BioCardia Inc (NAS:BCDA)

$ 2.43 0.05 (2.1%) Market Cap: 8.51 Mil Enterprise Value: 8.05 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 48/100

Q2 2024 BioCardia Inc Earnings Call Transcript
Aug 13, 2024

$2.64 (+4.27%)

Earnings
Q1 2024 BioCardia Inc Earnings Call Transcript
May 14, 2024

$5.94 (+1.23%)

Earnings
Q4 2023 BioCardia Inc Earnings Call Transcript
Mar 27, 2024

$6.29 (-0.21%)

Earnings
Q3 2023 BioCardia Inc Earnings Call Transcript
Nov 08, 2023

$6.52 (+6.10%)

Earnings
Q2 2023 BioCardia Inc Earnings Call Transcript
Aug 09, 2023

$13.63 (+6.28%)

Earnings
Q1 2023 BioCardia Inc Earnings Call Transcript
May 10, 2023

$29.85 (+0.51%)

Earnings
Q4 2022 BioCardia Inc Earnings Call Transcript
Mar 29, 2023

$31.05 (-4.61%)

Earnings
Q3 2022 BioCardia Inc Earnings Call Transcript
Nov 09, 2022

$28.78 (+3.70%)

Earnings
Q2 2022 BioCardia Inc Earnings Call Transcript
Aug 10, 2022

$22.5 (+1.00%)

Earnings
BioCardia Inc at LD Micro Microcap Invitational Conference (Virtual) Transcript
Jun 08, 2021
BioCardia Inc The Big Biz Show Corporate Analyst Meeting Transcript
Aug 07, 2020

BioCardia Inc at LD Micro Microcap Invitational Conference (Virtual) Transcript

Jun 08, 2021 / 08:30PM GMT

Release Date Price: $69 (-0.86%)

Transcript

John Peyton

SRAX, Inc. - Moderator

Hi, my name is John Peyton, Business Development at Sequire, shareholder insight and acquisitions. I'm here to present Dr. Peter Altman, CEO of BioCardia, Inc. BioCardia is a clinical-stage regenerative medicines company that develops therapeutics for cardiovascular disease. The lead candidate is the CardiAMP cell therapy system for treatment of heart failure, and chronic myocardial ischemia, and allogenic cell therapy for cardiac and pulmonary disease. The company is based in San Carlos, California.

Dr. Altman, over to you.

Peter Altman

BioCardia, Inc. - President & CEO

Thank you, John. So BioCardia has been focused on bringing personalized medicine to cell therapy for cardiovascular disease. Our efforts today are extensive. And I'll detail them trying to stay at the top level.

Here's our standard forward-looking statements. And I'm going to drop off the screen just to essentially enable folks to understand our pipeline opportunities here.

So the primary reason to be interested in BioCardia

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.